Method of treatment using chemotherapy and erythropoietin

Details Method of treatment using chemotherapy and erythropoietin Method of treatment using chemotherapy and erythropoietin

1997-04-15

1999-07-13

Hutzell, Paula K.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 21, 514 12, 514922, A01N 3718, A61K 3800

Patent

active

059226749

ABSTRACT:
The use of human erythropoietin (EPO) to prevent or treat endothelial injury due to chemotherapy, radiation therapy, mechanical trauma, or to a disease state which damages the endothelium (such as inflammation, heart disease or cancer) is described. The use of EPO in conjunction with the administration of chemotherapeutic agents is described.

REFERENCES:
patent: 4745099 (1988-05-01), Akamatsu et al.
patent: 5635160 (1997-03-01), Stutts et al.
Taber's Cyclopedic Medical Dictionary, 1985.
16.sup.th Edition, Ed, c.c. Thomas, R.A. Davis C. Philadelphia, p. 767.
Anagnostou et al., "Erythropoietin Has A Mitogenic and Positive Chemotactic Effect on Endothelial Cells", Proc. Natl. Acad. Sci. USA, 87:5978-5982, (1990).
Carlini et al., "Recombinant Human Erythropoietin Stimulates Angiogenesis", Kidney International, 47:740-745 (1995).
Hand et al., "Erythropoietin Enhances Vascular Responsiveness to Norepinephrine in Renal Failure",Kidney International, 48:806-813 (1995).
Markham et al., "Epoetin Alfa, A Review of its Pharmacodynamic and Pharmacokinetic Properties and therapeutic Use in Nonrenal Applications", Drugs, 49(2):232-254 (1995).
Nagai et al., "Effects of rHuEpo on Cellular Proliferation and Endothelin-1 Production in Cultured Endothelial Cells", Nephrol Dial Transplant, 10:1814-1819 (1995).
Wrighton et al., "Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin", Science, 273:458-463 (1996).
Livnah et al., "Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8 .ANG.", Science, 273:464-471 (1996).
M. Cazzola; "Erythropoietin: biology and clinical applications"; Trends in Experimental and Clinical Medicine, 3:344-361 (1993).
Kuriyama et al.; "Evidence for Amelioration of Endothelial Cell Dysfunction by Erythropoietin Therapy in Predialysis Patients"; Am. J. Hyperten., 9(5):426-431 (1996).
International Search Report for PCT/US97/15966.
Coa et al., gro-.beta.,a-C-X-C-Chemokine, Is an Angiogenesis Inhibitor That Suppresses the Growth of Lewis Lung Carcinoma in Mice, J. Exp. Med. 182: 2069 (1995).
Kumar et al., Basic Pathology, W.B. Saunders Company, Philadelphia,194; (1992) pp. 194-195.
Kuwata et al., Treatment of Metastatic Liver Tumors By Intermittent Repetitive Injection of an Angiogenesis Inhibitor Using an Implantable Port System in a Rabbit Model, Kobe J. Med. Sci. 43(2):83-98 (1997).
Maier et al., In vitro inhibition of endothelial cell growth by the antiangiogenic drug AGM-1460 (TNP-470) and the anti-endoglin antibody TEC-11, Anti-Cancer Drugs 8:238 (1997).
Pluda J.M., Tumor-Associated Angiogenesis: Mechanisms, Clinical Implications, and Therapeutic Strategies, Seminars in Oncology, 24:203 (1997).
Yamaji et al., Brain Capillary Endothelial Cells Express Two Forms of Erythropoietin Receptor mRNA 239:494 (1996), Eur. S. Biochem.
Carlini et al., J. Am. Soc. Neph 7(9): 1559(ASN Program and Abstract; Abstract 1548)(1996).

Affiliated with

Also associated with

Rating

Method of treatment using chemotherapy and erythropoietin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treatment using chemotherapy and erythropoietin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment using chemotherapy and erythropoietin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2275687